Ceramide Nanoliposomes as Potential Therapeutic Reagents for Asthma
Cells · 11.02.2023 · 12 (4) · 591
DOI: 10.3390/cells12040591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 11.02.2023. Verfasst von Harumi Sakae und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata 573-0101, Japan. Hauptthemen laut MEDLINE: Asthma, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Ceramides are an emerging class of anti-inflammatory lipids, and nanoscale ceramide-delivery systems are potential therapeutic strategies for inflammatory diseases. This study investigated the therapeutic effects of ceramide nanoliposomes (CNL) on type 2 inflammation-based asthma, induced by repeated ovalbumin (OVA) challenges. Asthmatic mice intratracheally treated with ceramide-free liposomes (Ghost) displayed typical airway remodeling including mucosal accumulation and subepithelial fibrosis, whereas, in CNL-treated mice, the degree of airway remodeling was significantly decreased. Compared to the Ghost group, CNL treatment unexpectedly failed to significantly influence formation of type 2 cytokines, including IL-5 and IL-13, known to facilitate pathogenic production of airway mucus predominantly comprising MUC5AC mucin. Interestingly, CNL treatment suppressed OVA-evoked hyperplasia of MUC5AC-generating goblet cells in the airways. This suggests that CNL suppressed goblet cell hyperplasia and airway mucosal accumulation independently of type 2 cytokine formation. Mechanistically, CNL treatment suppressed cell growth and EGF-induced activation of Akt, but not ERK1/2, in a human lung epithelial cell culture system recapitulating airway goblet cell hyperplasia. Taken together, CNL is suggested to have therapeutic effects on airway remodeling in allergic asthma by targeting goblet cell hyperplasia. These findings raise the potential of ceramide-based therapies for airway diseases, such as asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata 573-0101, Japan.
- Department of Pharmacology, University of Virginia, Charlottesville, VA 22908-8735, USA.
ORCID-Profile: Masaya Matsuda, Todd E Fox, Kazuyuki Kitatani
Förderung
- JSPS KAKENHI
Zitieren
APA
Sakae, H., Ogiso, Y., Matsuda, M., Shimora, H., Deering, T., Fox, T. E., Kester, M., Nabe, T., & Kitatani, K. (2023). Ceramide Nanoliposomes as Potential Therapeutic Reagents for Asthma. Cells, 12(4), 591. https://doi.org/10.3390/cells12040591
Vancouver
Sakae H, Ogiso Y, Matsuda M, Shimora H, Deering T, Fox TE, et al. Ceramide Nanoliposomes as Potential Therapeutic Reagents for Asthma. Cells. 2023;12(4):591. doi:10.3390/cells12040591
BibTeX
@article{Sakae2023,
author = {Sakae, Harumi and Ogiso, Yuri and Matsuda, Masaya and Shimora, Hayato and Deering, Tye and Fox, Todd E and Kester, Mark and Nabe, Takeshi and Kitatani, Kazuyuki},
title = {Ceramide Nanoliposomes as Potential Therapeutic Reagents for Asthma},
journal = {Cells},
year = {2023},
volume = {12},
number = {4},
pages = {591},
doi = {10.3390/cells12040591}
}
EUVIMED